David Einstein

1.1K posts

David Einstein banner
David Einstein

David Einstein

@davidjeinstein

Disease Group Leader, GU Medical Oncology @BIDMChealth @DanaFarber_GU, Asst Prof @harvardmed, dad, cyclist, Far Side superfan

Massachusetts, USA Katılım Ocak 2015
719 Takip Edilen934 Takipçiler
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
So proud of @kor_shah, who is entering her final year in fellowship at @cityofhope and in the process of looking for jobs (hint, hint: if you have an open GU position, give her a ring!). Amazing that she was able to launch an impactful study in #testicularcancer, a disease that warrants more attention. Kudos to her mentor @arafflemd on this project. @DrChoueiri @tompowles1 @neerajaiims @PGrivasMDPhD @shilpaonc @PBarataMD @KellyNFitz @sandysrimd @DrRanaMcKay
English
1
8
31
5.5K
David Einstein
David Einstein@davidjeinstein·
Society guidelines matter. This is especially concerning for rural areas where family medicine training predominates.
BIDMC Cancer Center@BIDMC_CancerCtr

#AUA26 Highlight: Eric Macdonald, MD, resident @BIDMCUrology and @HeidiRayala present #prostatecancer screening (PCS) patterns among primary care physicians (PCPs) and the potential impact on patients. 💡 IM-trained PCPs were 28% more likely to receive PCS than FM-trained PCPs.

English
0
0
4
269
David Einstein
David Einstein@davidjeinstein·
@BrendonStilesMD Like @piet_ost and team, we believe novel endpoints like treatment-free survival are critical here. We use a partitioned survival approach to account for all patients from time of randomization and measure cumulative time on/off tx, with/without tox. x.com/davidjeinstein…
David Einstein@davidjeinstein

A BCR/early recurrent prostate cancer double-whammy today. Out in @IJROBP in a special SBRT issue, we propose Treatment-Free Survival as a novel endpoint in trials of met-directed tx +/- systemic therapy: sciencedirect.com/science/articl…

English
0
0
2
134
Brendon Stiles
Brendon Stiles@BrendonStilesMD·
Love the trial. Love and believe in the concept. But how can we convince the broader public of the value of LCT? More directly - is PFS right endpoint in LCT trials? Should it instead be OS, metastasis free survival, or duration on 1st line rx? Would love to hear thoughts!
David Palma, MD, PhD@drdavidpalma

This is a great thread about OLIGOMA. I would just add that we can't expect phase III data for each histology. Two large histology-specific phase III trials (HN and esophagus) just closed due to poor accrual. For SABR-COMET the strongest predictor of accrual was the level of equipoise of the referring physicians. Sometimes the referring physicians do not support randomization, which makes it difficult for us to do so. pmc.ncbi.nlm.nih.gov/articles/PMC57…

English
8
4
21
6.8K
Chad Tang, MD
Chad Tang, MD@ChadTangMD·
@GiulioFrancoli1 at #estro2026 presents early results of the randomized PERSIAN trial. Results are early showing excellent PSA response in both arms (mdt slightly better) but definitely more to come.
Chad Tang, MD tweet mediaChad Tang, MD tweet mediaChad Tang, MD tweet mediaChad Tang, MD tweet media
English
1
12
33
1.3K
Piet Ost
Piet Ost@piet_ost·
DART results: Darolutamide added to SBRT for PSMA PET recurrent mHSPC temporary improves PSA responses and MFS, with a temporary increase in hormonal G1-2 adverse events. Thank you to all the patients and Belgian collaborators. @ESTRO2026 @Bayer
Piet Ost tweet mediaPiet Ost tweet mediaPiet Ost tweet mediaPiet Ost tweet media
English
4
18
72
2.3K
David Einstein retweetledi
Melissa Abel, MD
Melissa Abel, MD@melissaabel20·
An important study that highlights the complexity of using PSMA PET as an endpoint. Prognostic significance of PSMA tumor volume varied between patients with low and high volume of disease (*particularly relevant for #PSMA+BCR):
Melissa Abel, MD tweet media
Louise Emmett@drlouiseemmett

Clink link to article in European Urology. PSMA total tumour volume at 3months predicts overall survival independent of treatment in ENZAp. This raises important questions about how we should be measuring progression on PSMA. @ANZUPtrials @PCF_Science authors.elsevier.com/a/1mv8014kpm4a…

English
1
5
13
3.2K
Lisa Chesner, PhD
Lisa Chesner, PhD@LChesNerd·
I am thrilled to share that I have joined the faculty in the Department of Urology at UCSF! I am so grateful for the support of my exceptional mentors, colleagues, and trainees who have contributed to this milestone.  Looking forward to what’s ahead for the Chesner Lab!
English
3
4
50
5.4K
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
Not how it works. Sponsors discuss with the FDA, but do not always align or follow FDAs advice. I have zero insights into this trial or what the outcome or any conversations with the FDA to be clear. Watch FDA ODACs (on youtube) and you can find many where Pazdur clearly pushes the sponsor why they ignored their advice.
English
2
1
4
466
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga@nataliagandur·
⭐ Surgery in high-risk prostate cancer — when is it enough? @OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin Presented by @declangmurphy 🔹 Super clear, dynamic and clinically practical talk — thank you! 🔹 Key messages: 🔹 1. Not all high-risk prostate cancer is the same → risk stratification is essential 🔹 2. Surgery alone may be reasonable in carefully selected patients 🔹 3. Best candidates: lower-volume high-risk disease, favorable high-risk features, negative metastatic staging 🔹 4. Very high-risk / STAMPEDE-like patients often require a multimodality approach 🔹 5. The role of PLND is being redefined, especially in the PSMA PET era 🔹 6. cN1 disease is shifting toward pelvic RT ± systemic therapy rather than surgery alone 🔹 Take-home: Surgery remains important — but the key is patient selection, risk biology and integration within multimodality care. @Uromigos @KOSJ12 @Tylersbrt @DrSpratticus #ProstateCancer #UroOncology #Oncology
Dra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet mediaDra. María Natalia Gandur Quiroga tweet media
English
3
24
47
3.1K
Tyler Seibert MD PhD
Tyler Seibert MD PhD@TylerSbrt·
Very interesting concept. Worth studying well in earlier lines?
OncoAlert@OncoAlert

Coverage of #APCCC26 🇨🇭 by @OncoAlert 🚨 Day Two Bipolar androgen therapy: Is there an indication to use it today? Presenter Dr. Andrew Armstrong 🇺🇸 Bipolar androgen therapy (BAT) is an investigational treatment of men with minimally symptomatic androgen pathway modulator resistant (APMR) prostate cancer, where cyclic high dose testosterone is alternated with ADT, benefiting approximately 30% of patients, and may resensitize to androgen receptor pathway inhibition and improve quality of life.  Challenges remain durability and predictors of benefit. #ProstateCancer #ProstateCancerWeek @APCCC_Lugano @Silke_Gillessen @AOmlin @weoncologists @declangmurphy @RenuEapen @DrYukselUrun @nataliagandur @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @Uromigos @EUplatinum

English
1
2
6
585
David Einstein
David Einstein@davidjeinstein·
@AdamRodmanMD Huge congrats! All my patients come to me pre-diagnosed, so I’m safe until you move this into treatment algorithms, right? :-)
English
0
0
0
101

Keşfet

@neerajaiims @ASCO @ggebraelmd @SWOG @OncoAlert @urotoday @montypal @DrChoueiri